Tagged with AstraZeneca,

Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…

Egypt Country President, Hatem Werdany, provides an overview of AstraZeneca’s 50+ year legacy in Egypt and outlines the company’s plans to launch up to 25 new products there over the next three years in areas such as respiratory disease and breast cancer, and its intention to expand  local manufacturing capabilities. He…

China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics.   Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…

Poland Some of the top stories emanating from Poland’s pharma industry, including Polish biotech Ryvu Therapeutics’ exclusive deal with Exelixis, the partnership between Polpharma and startup Pikralida on a promising epilepsy candidate and Adamed’s expansion of its laboratory facilities.   Exelixis and Ryvu Therapeutics Sign Agreement to Develop Novel STING Agonist-Based…

Spain Its unorthodox name reflecting a somewhat unconventional approach, mAbxience has achieved some significant milestones in its short history, including becoming the only privately-owned company in the world with less than 500 people to have launched a monoclonal antibody biosimilar. “This is not usually a small company game, and mAbxience did…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

Global AstraZeneca recently announced plans to continue investing in China, the company’s second largest market after the United States, with the construction of a production facility that will serve as its regional headquarters in Qingdao, Shandong. The plans were announced during the third Qingdao Multinationals Summit. “To further promote the development…

China Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential tool to shifting away from the country’s zero-COVID policy – is under threat from new mutations of the virus. Other…

Global The top COVID-19 Vaccines by revenue in 2021 and sales projections for 2022 based on Airfinity’s COVID-19 Vaccine Market Revenue Forecast 2022. Pfizer/BioNTech’s vaccine stands to make USD 42.69 billion in 2022, while Moderna’s product has projected sales of USD 25.71 billion. Projected USD 3.97 billion sales for Russia’s Sputnik…

Saudi Arabia Sameh ElFangary, Country President for GCC and Pakistan at AstraZeneca, highlights AstraZeneca’s alignment with, and commitment to, Saudi Arabia’s Vision 2030 and the opportunities that the Vision is creating. ElFangary also explains the significance of a new memorandum of understanding to create a clinical research hub in Riyadh and how…